Gilead Sciences Inc (GILD) (Q3 2026) Earnings Call Highlights: Base Business Surges 16%
Gilead Sciences reported Q3 2026 earnings, with base business sales up 16% YoY to $8.2B, driven by HIV, Trodelvy, and Livdelzi. HIV sales rose 18% to $6.2B, with Biktarvy hitting 53% US market share. Trodelvy sales increased 42% to $506M, while Livdelzi grew 93% to $203M. The company raised 2026 revenue guidance by $1.6B, expecting $31.0B-$31.3B in total sales. However, Biktarvy's Medicare price negotiation will reduce 2028 revenue by $1.5B.
How this was made
The 30-second read
Why it matters
The new guidance and pricing headwind provide a clear catalyst for short‑term price movement, while long‑term growth prospects remain strong.
Market read
First‑report earnings and guidance for a large‑cap biotech; material numbers and a regulatory pricing impact create immediate trading relevance.
What to watch
Potential upside from upcoming long‑acting oral PrEP launch and pipeline ADC programs not fully reflected in current pricing.
Background
Gilead's Q3 earnings call highlighted record HIV market share, rapid growth in oncology products, and a significant regulatory pricing impact on its flagship Biktarvy.
Ticker impact
Gilead disclosed Q3 2026 earnings with 16% base business growth and raised full-year revenue guidance to $31.0-$31.3B.
likely modest downside as investors price in the Medicare discount on Biktarvy, offset by strong growth in HIV and oncology sales
Guidance numbers are new and material; the disclosed pricing hit is a concrete headwind that traders will factor into the stock immediately.
Market effects
Strong HIV and oncology growth may buoy the biotech sector, while the IRA pricing rule could pressure other HIV drug makers.
U.S. investors will adjust exposure to Gilead and peers; limited immediate impact outside North America.
Gilead's guidance influences global biotech sentiment, especially for companies with similar HIV portfolios.
Counterpoint
The guidance raise may be overstated; the IRA discount could erode margins more than anticipated, presenting a short opportunity.
Key entities
- companyGilead Sciences Inc.
US‑listed biopharma company reporting Q3 2026 earnings.
- productBiktarvy
Gilead's HIV drug facing Medicare price negotiation.
